We compared two protocols for the expansion of human mesenchymal stromal cells (hMSCs) starting from diagnostic samples of BM aspirates (2-5 ml) or using the remnants in the bag and filter at the end of the BM infusions. The protocols differed in the presence of either 10% fetal bovine serum (FBS) or 5% platelet lysate (PL). We obtained a significantly (P ¼ 0.02) better expansion with PL, obtaining a median 1010-fold compared to 198-fold with a selected batch of FBS and in fewer days (29.8 in PL versus 41.4 in FBS). Overall, we recovered a variable number from 54.8 Â 10 6 to 365 Â 10 6 hMSCs in PL versus a variable number from 2.7 Â 10 6 to 31 Â 10 6 in FBS. No difference could be found in terms of gross morphology, differentiation potential, surface markers and immunological properties (inhibition of allogeneic PHA response and mixed lymphocyte reaction) of cells expanded with PL or FBS. The preparations were found within the range of acceptability for all the quality control criteria. Due to the clinical grade nature of the PL and the reproducibility of separate preparations, we propose this method to obtain hMSCs even from minute amounts of BM cells.
Introduction
Since their first description by Friedenstein et al., 1 human mesenchymal stem cells (hMSCs) hold promises for the treatment of several human diseases from acute graft versus host reactions in allogeneic BMTs and support of marrow failure to heart ischemia. [2] [3] [4] Nonetheless, the most utilized methods to produce mesenchymal stem cells require the addition of fetal bovine serum (FBS), which represents a concern for the safe administration in patients and is often criticized by the regulatory authorities responsible for the approval of somatic cell therapy experimental protocols. Furthermore, different batches of FBS give variable efficiencies of hMSCs expansion in vitro. Finally, relatively large amounts of BM harvest are generally required (50-100 ml) to reach sufficient numbers of hMSCs (from 0.5 to 5 Â 10 6 /kg). 2, [5] [6] [7] [8] [9] In order to try and improve the method of expansion of hMSCs in clinical grade conditions, we have added the platelet lysate (PL) commonly produced in the Blood Collection Facility for dermatologic or orthopedic procedures to substitute for the FBS and have performed a close comparison between a selected FBS batch and PL to reach clinically relevant numbers of hMSCs starting from minute amounts of BM cells.
We will use throughout the text the acronym hMSCs as referred to human mesenchymal stem cells as well as human mesenchymal stromal cells, as very recently debated in an International Commission. 10, 11 Materials and methods
Platelet lysate preparation
Each platelet lysate (PL) was obtained from a single allogenic platelet unit stored at À401C prepared by the Hospital Transfusion center. The platelet unit had been prepared from a whole blood (WB) donation following Standard Blood Bank Procedures. Briefly, the WB donation (450 ml) was collected into a quadruple blood-bag system (Baxter Health Care Corporation, Deerfield, IL, USA). Platelet-rich plasma was separated from WB by 'light-spin' centrifugation and the platelets were concentrated by a second 'heavy-spin' centrifugation, with subsequent removal of supernatant plasma (AABB Technical Manual, 14th edition, American Association of Blood Banks Ed, 8101 Glenbrook Road, Bethesda, MD 20814, USA). The standard platelet unit had a mean volume of 5075 ml with a mean platelet concentration of 1.270.4 Â 10 6 /ml. The lysate was then thawed, spun at 3000 r.p.m. for 10 min at room temperature and the supernatant removed, aliquoted and frozen at À201C until use.
Isolation and in vitro expansion of hMSCs BM aspirates were collected within the Transplantation Program of the Haematology Division. 2-5 ml heparinized diagnostic samples were obtained during the clinical follow up of patients previously treated by autologous or allogeneic BMT who were in complete confirmed hematologic remission after informed consent and separated by Ficoll-Hypaque gradients centrifugation (Lympholyte-H, Cedarlane, Ontario, Canada) to yield mononuclear cells.
In the case of bag washouts, total nucleated cells from filter and bag residues were obtained after two washings with 250 ml saline and centrifugation at 2000 r.p.m. for 5 min.
Cells were plated at 200 000 cells/cm 2 in DMEM low glucose medium (Gibco Invitrogen, Carlbad, CA, USA) containing gentamicin 0.1 mM (Mayne Pharma, Napoli, Italy) and heparin 1000 IU (Pfizer Italia, Latina, Italy) in the presence of either 5% PL or 10% FBS.
In a first series of experiments, we utilized an untested batch of FBS present in the laboratory (Euroclone, Milano, Italy, lot no. EU S003564). Subsequently, we used the batch selected from the EBMT MSC Expansion Consortium (Perbio Science, Etten Leur, Netherlands).
Non-adherent cells were removed after 3-4 days and fresh medium was added. At subconfluency, cells were recovered after Trypsin-EDTA (StemCell Technologies, Vancouver, British Columbia, Canada) treatment and subsequently replated at 3000 cells/cm 2 in the same medium.
Products quality controls and release criteria
The final cell products underwent all the established quality control tests that were planned to adhere to specific criteria, including:
Viability of 480% measured by 7-amino-actinomycin D ( stimulators were mixed with irradiated hMSCs at different doses, ranging from 1 Â 10 5 to 2.5 Â 10 4 in flat-bottomed 96-wells plates (Corning, New York, NY, USA) for 5 days. The final volume in all wells was always normalized to 200 ml. Controls with different amounts of stimulators were also tested against 1 Â 10 5 responders to evaluate cell crowding effects. Proliferation was measured on day 6 after a 15-h pulse with bromodeoxyuridine (BrdU) using a chemiluminescence immunoassay kit (Roche Diagnostics GmbH, Mannheim, Germany) that measures BrdU incorporation during DNA synthesis. The data are presented as levels of luminescence intensity (relative light units, rlu) for each experimental condition tested. Triplicate additional wells were used to assess viability by double staining cells with 7AAD according to the manufacturer's instructions (Beckman Coulter, Cassina de' Pecchi, Milano, Italy) and CD3 FITC (BD) by FACS analysis (FacsScan, BD).
PHA stimulation assays 1 Â 10 5 PBMCs were plated with irradiated hMSCs at different doses, ranging from 1 Â 10 5 to 2.5 Â 10 4 in flatbottomed 96-well plates (Corning) and cultured for 5 days in RPMI 1640 medium supplemented with 10% heatinactivated human AB serum (Euroclone, Wetherby, West Yorkshire, UK) and PHA at a final concentration of 10 mg/ml. PBMCs proliferation was measured using BrdU chemiluminescence assay kit as above.
Statistical analysis
The cumulative cell counts under the two different culture conditions (PL and FBS) were compared using the multivariate analysis of variance test. An analysis of variance of contrast variables was performed to evaluate the successive differences between the two conditions in time measures.
P-values o0.05 were designated as significant for each test.
Results

Expansion of hMSCs is more efficient in PL than FBS-containing medium
In a first series of experiments, we compared the PL versus an untested batch of FBS that was available in the laboratory on the post Ficoll mononuclear cell fractions derived from the BM aspirates from seven patients. Unfortunately, FBS cultures could be split and passaged only in two cases, while no growth could be measured in the remaining five cases (data not shown). By contrast, PL cultures were always obtained in 7/7 samples with a mean yield of 196.8 Â 10 6 (range from 10.7 Â 10 6 to 500 Â 10 6 ), data not shown.
We considered that, due to the well-known variability among batches of FBS, the extremely bad results obtained with this untested batch of FBS may mask the evaluation of the efficacy of the PL. Therefore, a batch of FBS was chosen based on previous observations by our and others laboratories, as discussed in the EBMT MSC expansion consortium and selected for optimal hMSCs growth support.
A similar series of experiment was then performed on five additional BM samples and data are shown in Figure 1 and Table 1 . The difference was statistically significant, with a P-value ¼ 0.02 analyzing curves at all time points. The difference was also significant when comparisons were made at specific time points ( þ 20 days P ¼ 0.0062, þ 30 days P ¼ 0.0149, þ 40 days P ¼ 0.0144).
Median fold expansions of 198 for the FBS cultures and of 1010 for the PL cultures were observed. Moreover, the P5 passage was reached after 29.8 days (range 24-34) in PL cultures, well before the P5 reached in FBS cultures at 41.4 days (range 34-51 days).
Overall, from 12 different BM diagnostic samples, we could grow hMSCs in all cases with a mean recovery at P5 of 167.5 Â 10 6 varying from 10.7 Â 10 6 to 500 Â 10
) and a mean 1182.1 expansion fold, varying from 21.4 to 2500 (median ¼ 846.5).
Finally, in two selected cases, we determined whether significant growth of hMSCs could be obtained starting from the washouts of the filters and the bags that were left over after the transplant procedure and would otherwise have been discarded. Data in Table 2 show that starting from 0.4 Â 10 6 cells at P1 (mean value), final yield of mean 264.9 Â 10 6 cells could be recovered after 41.5 days (716 mean fold expansion).
In a separate series of experiments, we also compared different batches of PL, but they showed in all cases comparable expansion efficiencies (data not shown). Moreover, the platelet content per single unit did not vary significantly and ranged from 0.3 to 0.5 Â 10 11 in 50-70 ml suspension plasma. Indeed, their protein content (determined by Bio-Rad protein assay colorimetric test) varied from 10.05 to 12.19 mg/ml in several platelets preparations (data not shown).
We conclude that the addition of PL instead of FBS allows more efficient in vitro expansion of hMSCs from either BM mononuclear cells or from BM filter and bag washouts.
Morphology, phenotype and differentiation potential of in vitro expanded hMSCs In order to fully characterize the hMSCs expanded using the two different culture conditions, a number of parameters were investigated. No evident gross discrepancy was ever noted in morphology at the inverted miscroscope during the culture period (Supplementary Figure 1 , panels a and b, t ¼ 0). We then compared the immunophenotype of the final populations obtained. Cells expanded in PL or FBS did not differ from each other and consistently shared the same 'mesenchymal stem cell phenotype', that is, positivity for the CD90, CD73 and CD105 markers and negativity for CD45, CD34, CD14 and HLA-DR markers. A representative phenotypic analysis of PL expanded cells is shown in Figure 2 , demonstrating the homogeneity of the phenotype. Table 3 reports the results of the analysis comparing the phenotype of FBS and PL-expanded cells of four independent preparations as means and s.d., even if all preparations have been tested for phenotype (data not shown). The data clearly show that cells did not differ in terms of pattern of Ag expression, although small differences in intensities of expression of some Ags, in particular CD90, could be observed (Table 3) .
We then explored the differentiation potential towards adipocytes and osteoblasts of the two hMSC populations: both populations were able to differentiate as expected, as demonstrated by specific stainings with Sudan black and APAAP, respectively. No significant difference could be observed between the two different hMSCs in these assays (Supplementary Figure 1, panels b-i) . 
Functional properties of in vitro expanded hMSCs
We have finally evaluated some of the immunological properties of hMSCs expanded according to the two different protocols: as previously reported, hMSCs were able to dramatically reduce the mitogenic responses of allogeneic T lymphocytes to PHA mitogen and no difference was observed in the efficacy of graded numbers of cells when prepared either in standard or in PL conditions ( Figure 3) . Similarly, a dose-dependent inhibition of allogenic mixed lymphocyte reactions (MLRs) was noted when third party mesenchymal stem cells were added to the culture. This effect was observed irrespective of whether cells were produced in presence of FBS or in PL. A representative example is shown in Figure 4 . In all experiments, we have controlled the immunosuppressive activity of hMSCs against several control MLR wells containing variable amounts of stimulators to check for the crowding effects (Figure 4) . Quality controls for production in GMP Finally, at the end of culture, all hMSC products obtained were tested for all standard quality controls required for cell therapy products produced in good manufacturing practice (GMP) conditions, including sterility, endotoxin, mycoplasma and cell viability assays, all performed with validated tests and procedures. The cell products were found to fall within the acceptable ranges in all cases and, as such, were theoretically releasable for clinical use (data not shown). 
Discussion
In this report, we have shown that small amounts (diagnostic) of 12 BM samples (2-5 ml) or the residues of two filtered BM harvests (filter and bag washouts) are suitable for the production of high numbers of mesenchymal stem cells (from 10.7 Â 10 6 to 500 Â 10 6 cells), by in vitro expansion in five passages obtained in a median of 31 days of continuous culture.
The method developed here makes use of PL, a product obtained from blood donors and already available in most hospital and transfusion centers, and which is prepared according to standardized clinical grade procedures in closed systems. Indeed, we show that the addition of 5% of lysate is sufficient to produce clinically relevant numbers of hMSCs starting from less than 100 Â 10 6 BM nucleated cells. By comparison, it is interesting that, in our hands, the use of a pre-screened and selected batch of FBS is clearly inferior even if still able to expand hMSC cells in all tested cases. The differences observed with the use of PL were statistically significant. On the other hand, the need to obtain large marrow donations (up to 100 ml) may not be compatible with many declared clinical utilizations (autologous implants in ischemic heart diseases, as an example). 3, 4, 12 The FBS has been traditionally utilized to expand hMSCs, but generates the greatest concerns by the regulatory authorities for the intrinsic risk of transmitting animal diseases of yet unknown origin and for being the source of animal Ags. Therefore, the addition of a clinical grade product (PL) instead of FBS must be considered a major achievement. Many studies have been performed to try and substitute the animal serum with human autologous or allogeneic serum or with synthetic media, but have not usually produced satisfactory results. [13] [14] [15] The addition of the PL has been suggested previously, [16] [17] [18] but the exact determination of hMSC yield starting from a reduced number of nucleated cells to reach clinically relevant numbers has never been shown previously.
From the stand point of the compliance with the required criteria for somatic cell therapy experimental protocols, it is important to consider that all blood donations (and therefore also the platelet lysates when collected in accredited Blood Donation Centers) occur after careful and documented complete screening of the donors for the major infectious diseases (HIV I and II, CMV, hepatitis B virus (HBV), hepatitis C virus (HCV), syphilis). Finally, when we looked for the possible variation among different batches, we observed that most of them contain very comparable amounts of platelets and total proteins.
For the sake of completeness, we also tested our products at the end of the expansion protocol with the complete battery of standardized quality controls in our GMP facility and found them always adequate for clinical use (that is, viability over 90%, absence of bacterial, fungal contamination and mycoplasma, endotoxin levels below 2.5 IU/ml), thus confirming the reproducibility and suitability of the procedure in GMP conditions. Preliminary data show no prevalent gross karyotyping lesion (data not shown), in contrast to the recent report of spontaneous transformation of hMSCs. 19 We have used throughout the text the acronym hMSCs to refer to human mesenchymal stem cells as well as human mesenchymal stromal cells, as very recently debated in International Commissions.
10,11 Indeed, we have only characterized the osteogenic and the adipogenic differentiation and therefore we cannot reach any conclusion as to the multilineage differentiation capacity of these cells.
Finally, we fully characterized functionally and phenotypically the hMSCs obtained using the two protocols. This analysis demonstrated that the cells obtained did not differ significantly in terms of morphology and phenotype, using a panel of monoclonal antibodies of known reactivity with hMSCs. Furthermore, both cell products had evident immunosuppressive properties against allogeneic PHA T blasts and when added as third party in allogenic MLR responses. Finally, both populations showed osteogenic and adipogenic differentiation capacity. Altogether, these data suggest that hMSCs expanded in PL or FBS are very similar phenotypically and functionally, although we cannot exclude that they may differ for some yet untested property. It is nonetheless worthy of note, considering what today has to be considered to be the gold standard for MSC generation (as defined by the Mesenchymal and Tissue Stem Cell Committee of the ISCT), 10 that the cells grown here in the presence of PL can be considered bona fide hMSCs.
